Carmed Pharmaceuticals, a science-driven company specializing in standardized carvacrol-based formulations, is expanding into the United States market under the leadership of its founder, Mustafa Can. The U.S. expansion follows years of research and formulation development led by Can, who established Carmed Pharmaceuticals in 2019 after several years of prior scientific exploration focused on standardized botanical bioactives and mechanism-based product design.
Mustafa Can founded Carmed Pharmaceuticals with the goal of developing scientifically structured botanical formulations built on measurable mechanisms of action and rigorous quality control rather than trend-driven supplement concepts. Before founding the company, Can built his career in the maritime industry as a ship master, but a personal fascination with longevity and preventive wellness set him on an unexpected new course about a decade ago. Without formal scientific training, Can immersed himself in an intense period of self-directed study—reviewing thousands of scientific publications and exploring the chemistry of botanical compounds used in traditional medicine.
Today, Carmed operates with a research-driven framework that includes in vitro analysis, mechanism-based evaluation, formulation standardization, and structured quality control processes. All Carmed products are manufactured in facilities operating in accordance with Good Manufacturing Practice (GMP) principles and relevant regulatory standards. The company operates with a core team of approximately 25 full-time professionals and collaborates with a broader network of physicians, researchers, laboratories, and medical institutions involved in formulation development and scientific evaluation of bioactive compounds.
As part of its U.S. expansion, Carmed Pharmaceuticals plans to introduce several of its flagship formulations: Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, Vacrol-M® Capsule, and Omevaq-3®. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. According to Can, Carmed's development strategy focuses on combining botanical bioactives in standardized formulations designed to interact across multiple biological pathways.
Carmed's research efforts are supported by collaborations with academic institutions, laboratories, and medical researchers involved in formulation science and bioactive compound evaluation. In January 2026, a study published in the peer-reviewed journal Plants examined Vacrol® and S-Mix® in preclinical laboratory and in ovo models as part of broader scientific investigation into carvacrol-based formulations and multicomponent botanical interactions. The company emphasizes that such research reflects scientific investigation into botanical bioactivity and formulation design and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
As it enters the United States, Carmed states its strategy is focused on regulatory alignment, scientific credibility, and long-term positioning within the preventive wellness sector. Distribution timelines and retail availability for the United States will be announced in the coming months. The company's approach integrates traditional botanical knowledge with modern pharmaceutical methodology to create formulations designed to support immune resilience, cellular health, and overall physiological balance. More information about Carmed Pharmaceuticals is available at https://www.carmedpharmaceuticals.com.
